Comparison of FP-CIT SPECT with F-DOPA PET in patients with de novo and advanced Parkinson's disease

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 33, Issue 2, 2006, Pages 200-209

  Eshuis, S A ^a   Maguire, R P ^a   Leenders, K L ^a   Jonkman, S ^a   Jager, P L ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Dopamine transporter; F DOPA PET; FP CIT SPECT; Parkinson's disease

Indexed keywords

DOPA; DOPAMINE TRANSPORTER; IODINE 123; N OMEGA FLUOROPROPYL 2BETA CARBOMETHOXY 3BETA (4 IODOPHENYL)NORTROPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE DURATION; DOPAMINERGIC SYSTEM; ENZYME ACTIVITY; FEASIBILITY STUDY; FEMALE; HUMAN; MALE; MOTOR SYSTEM; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PUTAMEN; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARD;

ADULT; AGED; DIHYDROXYPHENYLALANINE; DOPA DECARBOXYLASE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MEMBRANE TRANSPORT PROTEINS; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 31444451405     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-005-1904-y     Document Type: Article

References (42)

1. Hughes AJ, Daniel SE, Blankson S, Lees AJ. A clinicopathological study of 100 cases of Parkinson's disease. Arch Neurol 1993;50:140-8
2. Hughes AJ, Daniel SE, Ben Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain 2002;125:861-70
3. 123I-FP-CIT SPECT striatal uptake. Mov Disord 2000;15:692-8
4. 123I]FP-CIT SPECT shows a pronounced decline of striatal dopamine transporter labelling in early and advanced Parkinson's disease. J Neurol Neurosurg Psychiatry 1997;62:133-40
5. Kazumata K, Dhawan V, Chaly T, Antonini A, Margouleff C, Belakhlef A, et al. Dopamine transporter imaging with fluorine-18-FPCIT and PET. J Nucl Med 1998;39:1521-30
6. Marek KL, Seibyl JP, Zoghbi SS, Zea-Ponce Y, Baldwin RM, Fussell B, et al. [I-123] beta-CIT/SPECT imaging demonstrates bilateral loss of dopamine transporters in hemi-Parkinson's disease. Neurology 1996;46:231-7
7. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995;38:589-98
8. Seibyl JP, Marek K, Sheff K, Zoghbi S, Baldwin RM, Charney DS, et al. Iodine-123-beta-CIT and iodine-123-FPCIT SPECT measurement of dopamine transporters in healthy subjects and Parkinson's patients. J Nucl Med 1998;39:1500-8
9. Tissingh G, Booij J, Bergmans P, Winogrodzka A, Janssen AG, van Royen EA, et al. Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iodophenyl) tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease. J Nucl Med 1998;39:1143-8
10. 123I] beta-CIT SPECT. J Neurol 1998;245:14-20
11. Ishikawa T, Dhawan V, Kazumata K, Chaly T, Mandel F, Neumeyer J, et al. Comparative nigrostriatal dopaminergic imaging with iodine-123-beta CIT-FP/SPECT and fluorine-18-FDOPA/PET. J Nucl Med 1996;37:1760-5
12. de Vries EFJ, Luurtsema G, Brussermann M, Elsinga PH, Vaalburg W. Fully automated synthesis module for the high yield one-pot preparation of 6-[F-18]fluoro-L-DOPA. Appl Radiat Isotopes 1999;51:389-94
13. Dhawan V, Ma Y, Pillai V, Spetsieris P, Chaly T, Belakhlef A, et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med 2002;43:1324-30
14. Ashburner J, Friston K. Multimodal image coregistration and partitioning - a unified framework. Neurolmage 1997;6:209-17
15. Antonini A, Vontobel P, Psylla M, Gunther I, Maguire PR, Missimer J, et al. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995;52:1183-90
16. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, et al. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990;47:1290-8
17. Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, et al. Brain dopamine metabolism in patients with Parkinson's disease measured with positron emission tomography. J Neurol Neurosurg Psychiatry 1986;49:853-60
18. Goodman MM, Keil R, Shoup TM, Eshima D, Eshima L, Kilts C, et al. Fluorine-18-FPCT: a PET radio tracer for imaging dopamine transporters. J Nucl Med 1997;38:119-26
19. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, et al. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000;47:493-503
20. Zigmond MJ, Abercrombie ED, Berger TW, Grace AA, Stricker EM. Compensations after lesions of central dopaminergic neurons: some clinical and basic implications. Trends Neurosci 1990;13:290-6
21. Ito Y, Fujita M, Shimada S, Watanabe Y, Okada T, Kusuoka H, et al. Comparison between the decrease of dopamine transporter and that of L-DOPA uptake for detection of early to advanced stage of Parkinson's disease in animal models. Synapse 1999;31:178-85
22. Asenbaum S, Brucke T, Pirker W, Podreka I, Angelberger P, Wenger S, et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med 1997;38:1-6
23. Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord 2003;18:S43-S51
24. Ribeiro MJ, Vidailhet M, Loc'h C, Dupel C, Nguyen JP, Ponchant M, et al. Dopaminergic function and dopamine transporter binding assessed with positron emission tomography in Parkinson disease. Arch Neurol 2002;59:580-6
25. 123I]beta-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson's disease. J Neurol Neurosurg Psychiatry 2003;74:294-8
26. 123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med 2000;27:867-9
27. 123I]beta-CIT single-photon emission tomography in Parkinson's disease reveals a smaller decline in dopamine transporters with age than in controls. Eur J Nucl Med 1997;24:1171-4
28. van Dyck CH, Seibyl JP, Malison RT, Laruelle M, Zoghbi SS, Baldwin RM, et al. Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries. Am J Geriatr Psychiatry 2002;10:36-43
29. Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, et al. Dopamine transporters decrease with age. J Nucl Med 1996;37:554-9
30. Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brucke T. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord 2003;18:1266-72
31. Vingerhoets FJG, Snow BJ, Schulzer M, Morrison S, Ruth TJ, Holden JE, et al. Reproducibility of fluorine-18-6-fluorodopa positron emission tomography in normal human subjects. J Nucl Med 1994;35:18-24
32. Eidelberg D, Takikawa S, Dhawan V, Chaly T, Robeson W, Dahl R, et al. Striatal F-18 dopa uptake - absence of an aging effect. J Cereb Blood Flow Metab 1993;13:881-8
33. Sawle GV, Colebatch JG, Shah A, Brooks DJ, Marsden CD, Frackowiak RS. Striatal function in normal aging - implications for Parkinson's disease. Ann Neurol 1990;28:799-804
34. Kish SJ, Zhong XH, Hornykiewicz O, Haycock JW. Striatal 3,4-dihydroxyphenylalanine decarboxylase in aging: disparity between postmortem and positron emission tomography studies? Ann Neurol 1995;38:260-4
35. Pohjalainen T, Rinne JO, Nagren K, Syvalahti E, Hietala J. Sex differences in the striatal dopamine D2 receptor binding characteristics in vivo. Am J Psychiatry 1998;155:768-73
36. Rivest R, Falardeau P, Di Paolo T. Brain dopamine transporter: gender differences and effect of chronic haloperidol. Brain Res 1995;692:269-72
37. 18F]dopa PET. J Neurol Neurosurg Psychiatry 1998;64:314-9
38. 123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001;57:2089-94
39. 123I] IPT and single-photon emission tomography. Eur J Nucl Med 1997;24:415-21
40. Brucke T, Djamshidian S, Bencsits G, Pirker W, Asenbaum S, Podreka I. SPECT and PET imaging of the dopaminergic system in Parkinson's disease. J Neurol 2000;247 Suppl 4:IV/2-7
41. 123I]-FP- CIT study group. Mov Disord 2000;15:503-510
42. Booij J, Hemelaar TG, Speelman JD, de Bruin K, Janssen AG, van Royen EA. One-day protocol for imaging of the nigrostriatal dopaminergic pathway in Parkinson's disease by [123I] FPCIT SPECT. J Nucl Med 1999;40:753-761